[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520112":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":49,"centralContacts":53,"locations":62,"responsibleParty":328,"collaborators":29,"id":330,"slug":331,"hasResults":332,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":332,"sex":338,"minAge":339,"maxAge":29,"enrollmentInfo":340,"targetDuration":29,"studyType":343,"phases":344,"briefSummary":346,"conditions":347,"keywords":350,"overallStatus":65,"whyStopped":29,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":361},{"fullName":5,"class":6},"Jules Bordet Institute","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional arm","EXPERIMENTAL","* SCRT (5 fractions of 5 Gy)\n* Surgery (according to the principle of TME) or watch \\& wait\n* Optional adjuvant chemotherapy\n\nOR\n\n* LCCRT (25-28 fractions of 1.8-2.0 Gy each +\u002F- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) followed by\n* Surgery (according to the principles of TME) or watch \\& wait, followed by\n* Optional adjuvant chemotherapy",[13,14,15,16],"Radiation: Short course radiotherapy","Drug: Adjuvant chemotherapy (optional)","Procedure: Total mesorectal excision","Radiation: Long course chemoradiotherapy",{"label":18,"type":19,"description":20,"interventionNames":21},"TNT arm","ACTIVE_COMPARATOR","Rapido regimen:\n\n* SCRT (5 fractions of 5 Gy)\n* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)\n* Surgery (according to the principle of TME) or \"watch \\& wait\"\n\nOr\n\nRapido light regimen:\n\n* SCRT\n* Up to 12 weeks of oxaliplatin based chemotherapy\n* Surgery or \"watch \\& wait\"\n\nOr\n\nOPRA with induction chemotherapy (INCT-CRT) regimen:\n\n* Up to 16 weeks of oxaliplatin-based chemotherapy\n* CRT (25-28 fractions of 1.8-2.0 Gy each +\u002F- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine)\n* Surgery or \"watch \\& wait\"\n\nOr\n\nOPRA with consolidation chemotherapy (CRT-CNCT) regimen:\n\n* CRT\n* Up to 16 weeks of oxaliplatin-based chemotherapy\n* Surgery or \"watch \\& wait\"",[15,22],"Combination Product: Total neoadjuvant therapy",[24,30,35,40,45],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"RADIATION","Short course radiotherapy","Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.",[9],null,{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":29},"DRUG","Adjuvant chemotherapy (optional)","The choice of the adjuvant chemotherapy is to the investigator's discretion.",[9],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":29},"PROCEDURE","Total mesorectal excision","Surgery must be performed according to the principles of total mesorectal excision. A \"watch \\& wait\" approach is allowed for those subjects who have clinical complete response according to the local assessment.",[9,18],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":29},"COMBINATION_PRODUCT","Total neoadjuvant therapy","The choice of the TNT is left to the investigator's discretion.\n\nIf RAPIDO:\n\n* SCRT (5 fractions of 5 Gy), followed by\n* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)\n\nIf RAPIDO light:\n\n* SCRT (5 fractions of 5 Gy), followed by\n* Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)\n\nIf OPRA with induction chemotherapy:\n\n* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by\n* CRT (25-28 fractions of 1.8-2.0 Gy each +\u002F- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine)\n\nIf OPRA with consolidation chemotherapy:\n\n* CRT (25-28 fractions of 1.8-2.0 Gy each +\u002F- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine) followed by\n* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)",[18],{"type":25,"name":46,"description":47,"armGroupLabels":48,"otherNames":29},"Long course chemoradiotherapy","Patients will receive 25-28 fractions of 1.8-2.0 Gy each +\u002F- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion fluorouracil or capecitabine",[9],[50],{"name":51,"affiliation":5,"role":52},"Francesco Sclafani","STUDY_CHAIR",[54,59],{"name":55,"role":56,"phone":57,"phoneExt":29,"email":58},"Sophie Lepannetier, phD","CONTACT","+32 (0)2 541 34 56","ctsu.shapers@hubruxelles.be",{"name":60,"role":56,"phone":61,"phoneExt":29,"email":58},"Ikram El Idrissi","+32 (0)2 541 30 81",[63,83,97,111,127,141,155,166,181,195,210,224,239,254,269,280,291,305,318],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"ZAS Antwerpen","RECRUITING","Antwerp","Antwerpen","2610","Belgium","BE",{"type":72,"coordinates":73},"Point",[74,75],4.40026,51.22047,{"lat":75,"lon":74},[78,81],{"name":79,"role":56,"phone":29,"phoneExt":29,"email":80},"Ines Joye, MD","ines.joye@gza.be",{"name":79,"role":82,"phone":29,"phoneExt":29,"email":29},"PRINCIPAL_INVESTIGATOR",{"facility":84,"status":65,"city":85,"state":67,"zip":86,"country":69,"countryCode":70,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"UZA Antwerpen","Edegem","2650",{"type":72,"coordinates":88},[89,90],4.44504,51.15662,{"lat":90,"lon":89},[93,96],{"name":94,"role":56,"phone":29,"phoneExt":29,"email":95},"Timon Vandamme, MD","oncotrials@uza.be",{"name":94,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":98,"status":65,"city":99,"state":67,"zip":100,"country":69,"countryCode":70,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"AZ Turnhout","Turnhout","2300",{"type":72,"coordinates":102},[103,104],4.94471,51.32254,{"lat":104,"lon":103},[107,110],{"name":108,"role":56,"phone":29,"phoneExt":29,"email":109},"Leen Mortier, MD","leen.mortier@azturnout.be",{"name":108,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":112,"status":65,"city":113,"state":114,"zip":115,"country":69,"countryCode":70,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Institut Jules Bordet","Anderlecht","Brussels Capital","1070",{"type":72,"coordinates":117},[118,119],4.31454,50.83619,{"lat":119,"lon":118},[122,125],{"name":123,"role":56,"phone":29,"phoneExt":29,"email":124},"Rita Institut Jules Bordet, MD","rita.saudeconde@hubruxelles.be",{"name":126,"role":82,"phone":29,"phoneExt":29,"email":29},"Rita Saude Conde, MD",{"facility":128,"status":65,"city":129,"state":114,"zip":130,"country":69,"countryCode":70,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Chirec Delta","Auderghem","1160",{"type":72,"coordinates":132},[133,134],4.43333,50.81667,{"lat":134,"lon":133},[137,140],{"name":138,"role":56,"phone":29,"phoneExt":29,"email":139},"Francesco Puleo, MD","francesco_puleo@hotmail.com",{"name":138,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":142,"status":65,"city":143,"state":114,"zip":144,"country":69,"countryCode":70,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"CHU Saint-Pierre","Brussels","1000",{"type":72,"coordinates":146},[147,148],4.34878,50.85045,{"lat":148,"lon":147},[151,154],{"name":152,"role":56,"phone":29,"phoneExt":29,"email":153},"Amelie Deleporte, MD","amelie.deleporte@stpierre-bru.be",{"name":152,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":156,"status":65,"city":143,"state":114,"zip":157,"country":69,"countryCode":70,"cosmosGeoPoint":158,"geoPoint":160,"contacts":161},"CHU Brugmann","1020",{"type":72,"coordinates":159},[147,148],{"lat":148,"lon":147},[162,165],{"name":163,"role":56,"phone":29,"phoneExt":29,"email":164},"Sylvie Lecomte, MD","sylvie.lecomte@chu-brugmann.be",{"name":163,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":167,"status":65,"city":168,"state":169,"zip":170,"country":69,"countryCode":70,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"UZ Gent","Ghent","East Flanders","9000",{"type":72,"coordinates":172},[173,174],3.71667,51.05,{"lat":174,"lon":173},[177,180],{"name":178,"role":56,"phone":29,"phoneExt":29,"email":179},"Karen Geboes, MD","karen.geboes@uzgent.be",{"name":178,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":182,"status":65,"city":183,"state":169,"zip":184,"country":69,"countryCode":70,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"AZ Nikolaas","Sint-Niklaas","9100",{"type":72,"coordinates":186},[187,188],4.1437,51.16509,{"lat":188,"lon":187},[191,194],{"name":192,"role":56,"phone":29,"phoneExt":29,"email":193},"Willem Lybaert, MD","willem.lybaert@telenet.be",{"name":192,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":196,"status":65,"city":197,"state":198,"zip":199,"country":69,"countryCode":70,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Hôpital de Jolimont","Haine-Saint-Paul","Hainaut","7100",{"type":72,"coordinates":201},[202,203],4.1885,50.45544,{"lat":203,"lon":202},[206,209],{"name":207,"role":56,"phone":29,"phoneExt":29,"email":208},"Alexandre Dermine, MD","Alexandre.DERMINE@jolimont.be",{"name":207,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":211,"status":65,"city":212,"state":198,"zip":213,"country":69,"countryCode":70,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Epicura","Hornu","7301",{"type":72,"coordinates":215},[216,217],3.82736,50.4328,{"lat":217,"lon":216},[220,223],{"name":221,"role":56,"phone":29,"phoneExt":29,"email":222},"Sandra Mupingu, MD","sandra.mupingumwanawa@epicura.be",{"name":221,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":225,"status":226,"city":227,"state":198,"zip":228,"country":69,"countryCode":70,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"CHU Ambroise Pare","NOT_YET_RECRUITING","Mons","7000",{"type":72,"coordinates":230},[231,232],3.95229,50.45413,{"lat":232,"lon":231},[235,238],{"name":236,"role":56,"phone":29,"phoneExt":29,"email":237},"Marie Diaz, MD","marie.diaz@helora.be",{"name":236,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":240,"status":65,"city":241,"state":241,"zip":242,"country":69,"countryCode":70,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"CHU de Liège - Sart Tilman","Liège","4000",{"type":72,"coordinates":244},[245,246],5.56749,50.63373,{"lat":246,"lon":245},[249,252],{"name":250,"role":56,"phone":29,"phoneExt":29,"email":251},"Elodie Gonne, MD","egonne@chuliege.be",{"name":253,"role":82,"phone":29,"phoneExt":29,"email":29},"Elodie GONNE, MD",{"facility":255,"status":65,"city":256,"state":257,"zip":258,"country":69,"countryCode":70,"cosmosGeoPoint":259,"geoPoint":263,"contacts":264},"CHA Libramont","Libramont","Luxemburg","6800",{"type":72,"coordinates":260},[261,262],5.37318,49.91741,{"lat":262,"lon":261},[265,268],{"name":266,"role":56,"phone":29,"phoneExt":29,"email":267},"Frederic Forget, MD","frederic.forget@vivalia.be",{"name":266,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":270,"status":271,"city":272,"state":273,"zip":274,"country":69,"countryCode":70,"cosmosGeoPoint":275,"geoPoint":279,"contacts":29},"Grand Hôpital De Charleroi","SUSPENDED","Charleroi","Namur","6000",{"type":72,"coordinates":276},[277,278],4.44448,50.41136,{"lat":278,"lon":277},{"facility":281,"status":226,"city":272,"state":273,"zip":282,"country":69,"countryCode":70,"cosmosGeoPoint":283,"geoPoint":285,"contacts":286},"CHU Charleroi","6042",{"type":72,"coordinates":284},[277,278],{"lat":278,"lon":277},[287,290],{"name":288,"role":56,"phone":29,"phoneExt":29,"email":289},"Angélique Covas, MD","angelique.covas@humani.be",{"name":288,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":292,"status":65,"city":293,"state":273,"zip":294,"country":69,"countryCode":70,"cosmosGeoPoint":295,"geoPoint":299,"contacts":300},"CHU UCL Namur","Godinne","5530",{"type":72,"coordinates":296},[297,298],4.87364,50.34809,{"lat":298,"lon":297},[301,304],{"name":302,"role":56,"phone":29,"phoneExt":29,"email":303},"Laurence FAUGERAS, MD","laurence.faugeras@chuuclnamur.uclouvain.be",{"name":302,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":306,"status":226,"city":273,"state":273,"zip":307,"country":69,"countryCode":70,"cosmosGeoPoint":308,"geoPoint":312,"contacts":313},"CHR Sambre et Meuse (site Meuse)","5000",{"type":72,"coordinates":309},[310,311],4.86746,50.4669,{"lat":311,"lon":310},[314,317],{"name":315,"role":56,"phone":29,"phoneExt":29,"email":316},"Yeter Gokburun, MD","yeter.gokburun@chrsm.be",{"name":315,"role":82,"phone":29,"phoneExt":29,"email":29},{"facility":319,"status":65,"city":273,"state":273,"zip":307,"country":69,"countryCode":70,"cosmosGeoPoint":320,"geoPoint":322,"contacts":323},"CHU St Elisabeth",{"type":72,"coordinates":321},[310,311],{"lat":311,"lon":310},[324,327],{"name":325,"role":56,"phone":29,"phoneExt":29,"email":326},"Donatienne Taylor, MD","donatienne.taylor@chuuclnamur.uclouvain.be",{"name":325,"role":82,"phone":29,"phoneExt":29,"email":29},{"type":329,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100520112","efficacy-and-safety-of-conventional-neoadjuvant-therapy-versus-total-neoadjuvant-therapy-in-older-patients-with-locally-advanced-rectal-cancer-100520112",false,"NCT06052332","Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer","Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer: a Multicentre, Open-label, Randomised Pragmatic Clinical Trial","SHAPERS","Inclusion Criteria:\n\n1. Age ≥ 70 years old\n2. ECOG performance status (PS):\n\n   * ≤1 if age \\> 75 years old\n   * ≤2 if age ≤ 75 years old\n3. Histologically or cytologically confirmed adenocarcinoma of the rectum\n4. Distal border of the tumour below the peritoneal reflection and within 15 cm of the anal verge\n5. Operable stage III or high-risk stage II rectal cancer (high-risk tumours defined as those having ≥1 of the following features: T4, mesorectal fascia (MRF) involvement\u002Fthreatening \\[i.e.,tumour within 1 mm of the MRF\\], extramural venous invasion). Patient with involvement of lateral pelvic lymph nodes are also eligible.\n6. Adequate bone marrow function as defined below:\n\n   * Absolute neutrophil count ≥1,500\u002FµL\n   * Haemoglobin ≥9 g\u002FdL\n   * Platelets ≥100,000\u002FµL\n7. Adequate liver function as defined below:\n\n   * Serum total bilirubin ≤1.5 x ULN. In case of known Gilbert's syndrome \\\u003C3xUNL is allowed\n   * AST (SGOT) and ALT (SGPT) ≤2.5 x ULN\n   * Alkaline phosphatase ≤2.5 x ULN\n8. Adequate renal function as defined by estimated glomerular filtration rate (GFR) ≥30 mL\u002Fmin\u002F1.73m² (according to the CKD-EPI 2021 equation).\n9. Absence of clinical conditions that in the opinion of the investigator, would contraindicate neoadjuvant therapy and\u002For surgery.\n10. Signed Informed Consent form (ICF) obtained prior to any study related procedure.\n11. Male subjects with partners of childbearing potential must agree to use condom during the course of this study and for at least 6 months after the last administration of study drugs.\n\nExclusion Criteria:\n\n1. Extensive growth into cranial part of the sacrum (above S2\u002F3 junction) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is achieved.\n2. Presence of metastatic disease or recurrent rectal tumour.\n3. Presence of grade ≥2 peripheral neuropathy according to the Common Toxicity Criteria for Adverse Events (CTCAE) v.5.0.\n4. Significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.\n5. Any contraindication to pelvic irradiation as evaluated by the investigator.\n6. Known hypersensitivity reactions to the study drugs or to any excipients, premedications or non-investigational medicinal products or concomitant medications.\n7. Any investigational anti-cancer therapy other than the protocol specified therapies (participation in other prospective studies which do not imply any specific intervention may be allowed after discussion with the Study Chair).\n8. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment.\n9. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident\u002Fstroke, myocardial infarction, unstable angina, congestive heart failure (grade III or IV as classified by the New York Heart Association), or serious cardiac arrhythmia requiring medication within the past 6 months.\n10. Complete dihydropyrimidine dehydrogenase (DPD) deficiency.\n11. Any previous treatment for rectal cancer.\n12. Use of brivudine, sorivudine or their chemically related analogues.","ALL","70 Years",{"count":341,"type":342},230,"ESTIMATED","INTERVENTIONAL",[345],"NA","The SHAPERS study is a multicentre, open-label, randomised, pragmatic clinical trial, comparing standard-of-care neoadjuvant treatment options for older (i.e., ≥70 years) subjects with high-risk stage II and stage III rectal cancer.",[348,349],"Locally Advanced Rectal Cancer","Older People",[351],"rectal cancer","2025-11-28",{"date":354,"type":355},"2025-12-05","ACTUAL",{"date":357,"type":355},"2024-02-07",{"date":359,"type":342},"2033-12",{"name":5,"class":6},19]